January 13, 2024
2 min watch
Save
VIDEO: Duker shares EyePoint pipeline progress
WAILEA, Hawaii — In this Healio video perspective from Hawaiian Eye/Retina 2024, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, discusses the phase 2 DAVIO 2 results for EYP-1901 for the treatment of wet AMD.
“The DAVIO 2 trial consisted of 160 patients randomly assigned to either 2 mg of EYP-1901 or 3 mg of EYP-1901 vs. an on-label aflibercept control,” Duker said. “The topline results showed that both doses of EYP-1901 were both essentially were equivalent for visual acuity to the on-label aflibercept; however, EYP-1901 can last between 6 months and up to 9 months with a single injection.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Duker reports being president and CEO of EyePoint Pharmaceuticals.
Read more about